pyridostigmine bromide

pyridostigmine bromide
Name	Pyridostigmine bromide
Tradename	Mestinon, Regonol
Routes	Oral, intravenous, intramuscular
Class	Acetylcholinesterase inhibitor
Legal	Prescription

pyridostigmine bromide

Pyridostigmine bromide is a reversible acetylcholinesterase inhibitor used chiefly to enhance neuromuscular transmission in disorders of the neuromuscular junction. It is prescribed worldwide and has been the subject of clinical studies, public health discussions, and regulatory review by agencies such as the Food and Drug Administration and the European Medicines Agency. The compound features in clinical practice guidelines from organizations including the World Health Organization and specialty societies in neurology and pharmacology.

Medical uses

Pyridostigmine bromide is primarily indicated for symptomatic treatment of myasthenia gravis, with utilization guided by recommendations from bodies such as the American Academy of Neurology, the National Institutes of Health, and national health services like the National Health Service (England). It is also used for reversal of nondepolarizing neuromuscular blockade in perioperative care under protocols by institutions including the American Society of Anesthesiologists and cited in textbooks by authors affiliated with Harvard Medical School and Johns Hopkins University. Off-label uses have appeared in case reports and reviews by clinicians at centers like the Mayo Clinic and Cleveland Clinic, and it has historical use in military contexts reviewed by committees of the United States Congress and reports from the Department of Defense (United States).

Pharmacology

Pyridostigmine bromide exerts its effect by reversible inhibition of acetylcholinesterase at the neuromuscular junction, enhancing availability of acetylcholine at synapses described in electrophysiology research from laboratories at institutions such as Massachusetts Institute of Technology, University of Oxford, and Stanford University. Pharmacodynamic and pharmacokinetic data have been published in journals associated with publishers like Elsevier, Springer Nature, and the New England Journal of Medicine. Metabolism and elimination profiles are discussed in clinical pharmacology texts used in curricula at Columbia University and University of California, San Francisco. Mechanistic models cite foundational work linked to researchers honored by awards such as the Nobel Prize in Physiology or Medicine.

Dosage and administration

Recommended dosing regimens for adults and pediatrics are provided in formularies maintained by organizations such as the British National Formulary, the United States Pharmacopeia, and hospital protocols at institutions like Massachusetts General Hospital. Typical oral doses, titration schedules, and parenteral dosing in acute care are described in guidelines from the Society for Critical Care Medicine and perioperative recommendations endorsed by the Royal College of Anaesthetists. Clinical trials reported by groups associated with universities like Yale University and University of Toronto inform adjustment for renal impairment referenced in nephrology resources from the American Society of Nephrology.

Side effects and contraindications

Common adverse effects such as gastrointestinal cramping, increased salivation, and bradycardia are reported in case series from centers including Mount Sinai Health System and regulatory safety communications from the Food and Drug Administration. Severe cholinergic crises and hypersensitivity reactions necessitate emergency protocols similar to those outlined by the American Heart Association and emergency medicine texts used at University College London Hospitals. Contraindications and cautions in patients with mechanical bowel obstruction or bronchospastic disease are cited in position statements by specialty groups like the European Respiratory Society and cardiology guidance by the European Society of Cardiology.

Interactions

Clinically significant interactions include antagonism or potentiation with agents used in anesthesia and critical care, as discussed in reviews from the American Society of Anesthesiologists and evidence syntheses by teams at Johns Hopkins Medicine. Interactions with cholinomimetics, anticholinergics, and neuromuscular blocking agents are detailed in pharmacology compendia produced by publishers such as Wolters Kluwer and in drug interaction databases used by health systems like the Veterans Health Administration. Reports involving polypharmacy in elderly populations reference geriatric guidance from the American Geriatrics Society.

Chemistry and formulations

Chemically, the molecule is a quaternary ammonium bromide salt with structural description found in chemical archives managed by institutions such as the Royal Society of Chemistry and the American Chemical Society. Formulations include immediate-release tablets and injectable solutions produced by pharmaceutical manufacturers reviewed under quality standards from the World Health Organization and pharmacopeias like the European Pharmacopoeia. Stability, storage, and excipient information are provided in product monographs submitted to national agencies including the Medicines and Healthcare products Regulatory Agency and catalogued by hospital pharmacies at systems such as Kaiser Permanente.

History and regulatory status

Development and clinical introduction were reported in clinical literature emerging from centers like University of Edinburgh and industrial research by companies later interacting with regulators including the Food and Drug Administration and the European Medicines Agency. Regulatory approvals, labeling changes, and safety communications have been the subject of oversight by parliamentary committees such as those in the United States Congress and reviews published in esteemed journals like The Lancet and the British Medical Journal. The drug’s use in military prophylactic programs prompted reports by the Department of Defense (United States) and investigations involving panels convened at institutions such as the National Academies of Sciences, Engineering, and Medicine.

Category:Cholinesterase inhibitors